| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.6 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.6 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |